Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hélène Landriault"'
Publikováno v:
The Journal of Clinical Pharmacology. 36:903-910
Dolasetron mesylate (MDL 73,147EF, Anzemet; Hoechst Marion Roussel, Laval, Canada) is a 5-HT3 receptor antagonist undergoing clinical evaluation for use as an antiemetic agent. The pharmacokinetics of dolasetron and its reduced metabolite (MDL 74,156
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a2871661da274e038cc7dd0087489f2
https://doi.org/10.1002/j.1552-4604.1996.tb04757.x
https://doi.org/10.1002/j.1552-4604.1996.tb04757.x
Publikováno v:
Biopharmaceutics & Drug Disposition. 15:207-215
In order to determine the potential pharmacokinetic drug interaction between ranitidine and diltiazem (DTZ), each of ten male beagle dogs, age 2.7-4.0 years, weight 13-16 kg, received a single oral dose of sustained release DTZ with and without previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4132b5e5bc9447ccf19abcedd15c4c4c
https://doi.org/10.1002/bdd.2510150303
https://doi.org/10.1002/bdd.2510150303
Autor:
Gilles Caillé, Sonia Guimont, Jean Spénard, E. Hutchings, Denis Gossard, Keith Klischer, Chantal Lambert, Anthony S. Russell, Manon Raymond, Michael Grace, Hélène Landriault
Publikováno v:
Biopharmaceutics & Drug Disposition. 14:767-778
Cardizem SR and Bi-Tildiem were both approved in their respective countries on the basis of clinical trials demonstrating efficacy and safety in the treatment of angina pectoris. In this cross-over randomized study, we assessed whether these two sust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b336fd02d283dcd5c22a213363f988e
https://doi.org/10.1002/bdd.2510140903
https://doi.org/10.1002/bdd.2510140903
Autor:
Gilles Caillé, Hélène Landriault, Jean Thiffault, Jean Spénard, Maria Perrotta, Gianfranca Picirilli, Manon Raymond, Y. Lacasse
Publikováno v:
Biopharmaceutics & Drug Disposition. 14:257-263
Twenty-four young healthy volunteers received a single dose of metformin 500 mg (Glucophage, Nordic Laboratories, Canada) in tablet form. Plasma concentrations were determined by HPLC in samples collected prior to and 0.33, 0.66, 1, 1.33, 1.66, 2, 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99b015758585426262ea7f40271a2853
https://doi.org/10.1002/bdd.2510140308
https://doi.org/10.1002/bdd.2510140308
Autor:
M Lefebvre, Hélène Landriault, Jean Spénard, Pierre Major, Gilles Caillé, John McCans, Jean-Marie Houle
Publikováno v:
Drug Investigation. 4:276-282
In a double-blind phase I study, healthy male volunteers were randomly assigned to receive clentiazem, a benzothiazepine calcium channel blocker (n = 24), or placebo (n = 3). Clentiazem was administered in increasing single oral doses of 0, 20, 40, 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26652ceb2273d015cc4f7b5df751b0ea
https://doi.org/10.1007/bf03258411
https://doi.org/10.1007/bf03258411
Autor:
M Lefebvre, Martin Juneau, Lisa Roberts, Mark Castles, Anther C. F. Keung, Denis Gossard, Jean Spénard, Hélène Landriault, Ellen Dempsey, Dan C. Dimmitt
Publikováno v:
Biopharmaceuticsdrug disposition. 18(4)
Twenty-four healthy women received 2.4 mg kg-1 dolasetron mesylate (1.8 mg kg-1 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74156 were mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afb5dcbb085a6183766ffda13fee1a8
https://pubmed.ncbi.nlm.nih.gov/9158883
https://pubmed.ncbi.nlm.nih.gov/9158883
Publikováno v:
Biopharmaceuticsdrug disposition. 17(2)
Twenty-three young, healthy, male volunteers received, in a randomized crossover design, 240 mg of a once-a-day diltiazem formulation at 08:00 (AM) or 22:00 (HS) for 6 days. A 7 day washout period was observed between the two modes of administration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37276962a0733c6cb892248796b51fd6
https://pubmed.ncbi.nlm.nih.gov/8907717
https://pubmed.ncbi.nlm.nih.gov/8907717
Autor:
Denis Gossard, P. du Souich, Jean Spénard, Gilles Caillé, D Geadah, Y Lacasse, M Lefebvre, Hélène Landriault, R Moisan
Publikováno v:
Biopharmaceuticsdrug disposition. 15(3)
Diltiazem is a calcium antagonist used in angina pectoris and hypertension. There is little information concerning the slow-release (SR) formulation in the literature. The pharmacokinetics of diltiazem SR (120 mg) have been assessed over a 36h period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29989caf8724818f4aa1dd717d0e9d4d
https://pubmed.ncbi.nlm.nih.gov/7880983
https://pubmed.ncbi.nlm.nih.gov/7880983